Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim PR Newswire - Thu Dec 4, 7:37AM CST

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) PR Newswire - Mon Dec 1, 11:00AM CST

LYMPHIR now available nationwide

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration PR Newswire - Fri Nov 21, 7:37AM CST

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules PR Newswire - Tue Oct 21, 3:30PM CDT

CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 1.1800 (-5.60%)
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules PR Newswire - Tue Oct 21, 7:00AM CDT

CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 1.1800 (-5.60%)
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch PR Newswire - Mon Oct 20, 7:37AM CDT

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR

CTXR : 1.1800 (-5.60%)
MCK : 808.62 (-0.68%)
CTOR : 1.1199 (+0.89%)
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR Newswire - Fri Oct 17, 4:00PM CDT

LD Micro Main Event XIX, October 19-21, 2025

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ PR Newswire - Thu Oct 16, 7:47AM CDT

EVERSANA  to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire - Wed Sep 10, 3:30PM CDT

CRANFORD, N.J. , Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma")...

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire - Tue Sep 9, 7:30AM CDT

CRANFORD, N.J. , Sept. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma")...

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)

Barchart Exclusives

Rate Decision, Tech Earnings and Other Key Things to Watch this Week Barchart - Sun Dec 7, 12:00PM CST
Markets face the year's final major policy week as the Federal Reserve's December meeting Wednesday afternoon will determine whether the central bank delivers another rate cut or pauses its easing cycle amid mixed economic signals and persistent inflation concerns. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot